GT Biopharma GTBP 深 沪
等待开盘 11-05 09:30:00 美东时间
0.618
-0.005
-0.82%
华盛通- 最 高0.623
- 今 开0.605
- 成交量 23.78万股
- 最 低 0.60
- 昨 收 0.6231
- 总市值 657.31万
- 52周最高 4.10
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.55
- 委 比 -5.05%
- 总股本 1063.61万
- 历史最高 591.99
- 量 比 0.58
- 振 幅 3.69%
- 历史最低 0.55
- 每 手 1
- 风险率 0.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation
Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 17, 2025 /PRNewswire/ -- Equity InsiderNews Commentary – MIT and Harvard scientists recently created...
10-17 21:50
Precision Oncology Approaches Drive $312B Market Transformation
USA News Group News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, Oct. 17, 2025 /PRNewswire/ -- USA News Group News Commentary – Biomarker-driven drug development accelerates ...
10-17 21:00
Next-Generation Targeted Therapies Reshape Precision Oncology Landscape
USA News Group News Commentary – Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 15, 2025 /PRNewswire/ -- USA News Group News Commentary – Biomarker-driven drug development is acc...
10-15 21:11
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Bluejay Diagnostics (NASDAQ:BJDX) shares rose 113.4% to $3.99 during T...
10-09 20:07
Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034
Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 8, 2025 /PRNewswire/ -- Ohio State researchers recently solved a critical mystery explaining why som...
10-08 22:58
GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies
GT Biopharma announced that enrollment in the Phase 1 trial for GTB-3650 is progressing well, with Cohort 3 patients initiating treatment without dose-limiting toxicities. The first Cohort 3 patient showed immune activation consistent with previous lower-dose cohorts. Cohort 4 dosing is planned by year-end 2025, with potential for up to 7 cohorts. Further updates are expected in Q1 2026.
10-08 13:00
Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms
Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 7, 2025 /PRNewswire/ -- Equity InsiderNews Commentary – Major pharmaceutical companies presenting at...
10-07 20:00
GT Biopharma to Participate in the Centurion One Capital 3rd Annual Bahamas Summit
GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company, announced that its CEO, Michael Breen, will participate in the Centurion One Capital 3rd Annual Bahamas Summit on October 28-29, 2025, in Nassau, Bahamas. The company will host one-on-one meetings during the conference. GT Biopharma focuses on developing immuno-oncology therapies using its proprietary TriKE® NK cell engager platform, licensed from the University of Minne...
10-06 13:00
GT Biopharma Alters Preferred Stockholder Rights
GT Biopharma ( ($GTBP) ) has issued an update. In September 2025, GT Biopharma‘...
09-27 04:53
GT Biopharma Waives Series L Stock Redemption Rights
GT Biopharma ( ($GTBP) ) just unveiled an announcement. In September 2025, GT B...
09-24 05:57
